Olanzapina in pazienti maniacali o misti con o senza abuso di sostanze

Translated title of the contribution: Olanzapine in manic/mixed patients with or without substance abuse

Gabriele Sani, Alessio Simonetti, Giulia Serra, Andrea Solfanelli, Nicoletta Girardi, Delfina Janiri, Emanuela Danese, Chiara Rapinesi, Roberto Tatarelli, Paolo Girardi

Research output: Contribution to journalArticlepeer-review


Aim. To evaluate the efficacy of olanzapine in patients in their manic/mixed phase with or without comorbidity with substance abuse/dependence disorder. Methods. In this observational, controlled, prospective study, 60 patients with a DSM-IV-TR diagnosis of bipolar disorder, manic/mixed episode (30 patiens with and 30 patient without comorbidity with a substance abuse/dependence disorder) were treated with olanzapine, evaluated at discharge, and followed- up for 8 weeks. Efficacy of olanzapine was assessed by comparing the proportion of responders (an at least 50% drop in Young Mania Rating Scale [YMRS] score from baseline) and remitters (YMRS ≤12 and Hamilton Depression Rating Scale [HAM-D] ≤8) in both groups. Craving and days of abuse/use were assessed with Visual Analogue Scale (VAS) and Time-line Follow-Back (TLFB), respectively. Results. Differences in response and remission percentages were statistically not significant at discharge and during follow-up. A reduction of days of abuse has been observed in the drug-abuse group, while craving was only slightly decreased. Discussion. These results suggest that olanzapine is effective in both groups and its efficacy in reducing the days of abuse appears to be independent from its action on craving.

Translated title of the contributionOlanzapine in manic/mixed patients with or without substance abuse
Original languageItalian
Pages (from-to)140-145
Number of pages6
JournalRivista di Psichiatria
Issue number2
Publication statusPublished - Mar 2013

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Olanzapine in manic/mixed patients with or without substance abuse'. Together they form a unique fingerprint.

Cite this